PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29382554-12	2018	Western blot analysis revealed that the expression level of 5-HT2A receptor was specifically decreased in the prefrontal cortex of mice that had been administered yokukansan and fluvoxamine.	Fluvoxamine	178-189	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	60-75	
16846619-0	2006	Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors.	Fluvoxamine	0-11	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	120-126	
16846619-6	2006	The antiallodynic effects of systemic fluvoxamine were also reduced by both systemic and intrathecal administration of ketanserin, a 5-HT2A/2C receptor antagonist.	Fluvoxamine	38-49	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	133-139	
16846619-8	2006	These results indicate that fluvoxamine exerts its antiallodynic effects on neuropathic pain via descending 5-HT fibers and spinal 5-HT2A or 5-HT2C receptors, and the antinociception on acute mechanical pain via 5-HT3 receptors.	Fluvoxamine	28-39	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	131-137	
24582626-11	2014	Expression of 5-HT2A and Sigma-1 receptors decreased after cDEX infusion compared with the saline group, and these decreases normalized to control levels upon Flu treatment.	Fluvoxamine	159-162	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	14-20